Isovurex (Ezetimibe)

Ezetimibe works by selectively blocking the NPC1L1 transporter on the surface of intestinal cells. This inhibition reduces the absorption of both dietary and biliary cholesterol, decreasing the amount of cholesterol delivered to the liver and ultimately lowering plasma LDL‑cholesterol concentrations.

The dosage of Isovurex is determined by the prescribing clinician based on the patient’s clinical condition, laboratory results, and any concomitant lipid‑lowering therapy. Physicians typically start with a standard dose and may adjust it according to therapeutic response and tolerability.

Safety data for ezetimibe during pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Isovurex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details, and any required import documentation.

The primary alternative to ezetimibe is statin therapy, which reduces cholesterol synthesis in the liver. Ezetimibe targets intestinal absorption, offering an additive effect when combined with statins. Compared with statins alone, ezetimibe generally has a lower risk of muscle‑related side effects but may be less potent in lowering LDL‑cholesterol when used as monotherapy.

Isovurex should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat, and direct sunlight to maintain stability and potency throughout the shelf life.

Isovurex is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the prescribing clinician’s instructions regarding timing relative to other medications.

Serious adverse events, though rare, include hepatitis, severe muscle toxicity (myopathy), and allergic reactions such as rash or swelling. Patients should promptly report symptoms like persistent abdominal pain, unexplained muscle weakness, jaundice, or signs of an allergic response to their healthcare provider.

Isovurex is contraindicated in individuals with known hypersensitivity to ezetimibe or any of the tablet’s excipients. Caution is advised for patients with active liver disease, severe renal impairment, or those who are pregnant or breastfeeding unless clearly indicated by a physician.